Home > Full Text Reviews > Denosumab versus Zoledronic Acid for...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cover of Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness

Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness

Rapid Response Report: Summary with Critical Appraisal

Copyright and Permissions

The purpose of this report is to evaluate the cost-effectiveness of denosumab and zoledronic acid for the treatment of postmenopausal women and men with osteoporosis, including women receiving adjuvant aromatase inhibitor therapy for non-metastatic breast cancer, men receiving androgen deprivation therapy for non-metastatic prostate cancer, and patients with severe renal dysfunction.

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that the Canadian Agency for Drugs and Technologies in Health (CADTH) could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright © 2016 Canadian Agency for Drugs and Technologies in Health.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

PMID: 28211663

Download

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...